Vancouver, British Columbia–(Newsfile Corp. – March 15, 2022) – Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (“ Entheon” or the “Company“), a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personalized treatment of addiction disorders, today announced that the first patient has been enrolled in the EBRX-101…


Previous articleBright Minds Biosciences Announces Successful Completion of 28-Day Toxicology Studies and Advancement to First-in-Human Clinical Trial
Next articleMINDCURE Provides Update on Strategic Review